Sepsis Therapeutics Market - By Treatment Type, By Disease Type, By End Use - Global Forecast 2025 - 2034

Sepsis Therapeutics Market Size

The global sepsis therapeutics market was estimated at USD 4 billion in 2024. The market is expected to grow from USD 4.2 billion in 2025 to USD 7.5 billion in 2034, at a CAGR of 6.7%. The rising incidence of sepsis is one of the major factors contribute to market growth.
 

An example would be the World Health Organization's report of May 2024 stating that there are 48.9 million cases of sepsis worldwide, out of which nearly 20 million approximately half are children below five years. Furthermore, sepsis occurs as a complication associated with healthcare in about 15 patients out of every 1,000 who are hospitalized. The rising population of elderly individuals also significantly contributes to the growth of the market.
 

This group especially is at severe risk because of their weakened immune systems which makes them more prone to falling sick. For instance, according to the National Institutes of Health (NIH), elderly patients account for approximately 58% to 65% of sepsis cases. In addition, a study published by SpringerOpen reported that over 100,000 emergency admissions related to sepsis, with the average patient age being 71 years.
 

Bacterial infections continue to dominate as the primary causative agents of sepsis, taking precedence over the fungal, viral, and parasitic infections. According to a 2022 report from Chest Journal, approximately 77.9% of global sepsis cases are caused by bacterial infections, with fungal infections accounting for about 14.1%. Progress in diagnostic tools, favorable regulatory support, and continuous innovation in drug development are contributing to better outcomes for patients. These advancements are facilitating earlier diagnosis, more targeted treatments, and personalized care strategies, all of which are propelling growth in the sepsis therapeutics market. As an example, in April 2024, the U.S. FDA authorized the use of Prenosis' Sepsis ImmunoScore an advanced diagnostic solution that uses artificial intelligence to identify sepsis and track patient recovery. This approval represents a major milestone in advancing hospital care and improving clinical decision-making for sepsis management.
 

Sepsis is a complicated and severe medical condition paired with infection. It arises as a result of the body’s overwhelming response to a sickness. If not treated properly, it can cause organ malfunction and death which makes urgent treatment critical. In a proportion of patients, the immune response is unusually created and instead of defending against the infection, the organism attacks healthy parts of the body causing inflammation that often leads to life-threatening conditions such as sepsis. The growing prevalence of sepsis demands new medically advanced treatment alternatives which, in turn, fuels market expansion.
 

Sepsis Therapeutics Market Trends

• The growth of market is significantly stimulated by technological advancements, introduction of advanced sepsis diagnostics tools and rising healthcare expenditure. For instance, the introduction of rapid diagnostic tests, such as B. multiplex PCR-based platforms, has significantly reduced the time required to detect sepsis. In addition, multiplex PCR tests enable the rapid identification of multiple pathogens responsible for sepsis, leading to faster and more accurate treatment decisions. This not only improves patient outcomes and compliance but also helps reduce the mortality rate associated with sepsis.
   
• Additionally, the ongoing research in immunomodulators such as monoclonal antibodies and personalized medicine biomarkers has proven effectiveness in treating sepsis. For example, therapies such as tocilizumab, which targets interleukin-6 (IL-6), helps modulate the hyperinflammatory response responsible for organ failure in septic patients.
   
• Moreover, combination therapies that include vitamins with corticosteroids such as combination with vitamin C, thiamine and hydrocortisone also known as HAT therapy are being used to enhance faster recovery of sepsis. This combination treatment helps fight infectious agents reduces inflammation prevent organ failure and ease coagulopathy, eventually improving patient survival.
   
• Moreover, the development of biomarkers such as procalcitonin (PCT) has improved monitoring and detection of sepsis in a better way. These biomarkers help with treatment decisions, optimize antibiotic use and cut-down unnecessary treatment. This can improve patient care and outcomes while reducing antibiotic resistance.
   
• Lastly, advancement in artificial intelligence (AI) and machine learning (ML) have improved the sepsis management. AI algorithm helps analyse large amounts of patient data, such as vital signs and laboratory results, to detect early signs of sepsis and predict its progression.
   
• Therefore, these innovations are expected to play a crucial role in stimulating the growth and effectiveness of sepsis treatments in the market during the analysis period.
   

Trump Administration Tariffs

• The tariffs on imports from China, including pharmaceutical components and packaging materials, implemented might increase the cost of raw materials and treatment devices in the sepsis therapeutics market. These tariffs can also lead to supply chain disruptions, as many sepsis treatment providers rely heavily on Chinese vendors for affordable drug ingredients, medical equipment, and packaging materials.
   
• Due to these tariffs, companies operating in the market might have to reevaluate and adjust their sourcing and production strategies to reduce dependency on Chinese suppliers. This might lead to a shift towards sourcing from alternative markets such as India, Vietnam, and Eastern Europe.
   
• Moreover, short-term challenges include delays in product availability, increased operational costs due to vendor diversification, and potential disruptions in after-sales support for medical devices, drug supply chains, and packaging systems.
   

Sepsis Therapeutics Market Analysis

In 2021, the global market was valued at USD 3.3 billion. The following year, it saw a slight increase to USD 3.5 billion, and by 2023, the market further climbed to USD 3.7 billion.
 

Based on treatment type, the global market is categorized in drugs, I.V fluids, oxygen therapy, surgery and other treatments. The drugs segment dominated the market in 2024 and was valued at USD 1.9 billion.
 

• The drug segment dominates the market due to the high reliance on antibiotics, antivirals drugs/antifungals drugs, and other essential medicines in the treatment of sepsis. Antibiotics remain the first-line treatment, with broad-spectrum antibiotics administered soon after diagnosis for controlling and preventing further complications.
   
• Additionally, vasoconstrictors, monoclonal antibiotics, and corticosteroids are essential components of adjunctive therapy in sepsis management. Vasoconstrictors like norepinephrine are crucial for stabilizing blood pressure during septic shock, while monoclonal antibiotics and immunomodulators help control the body’s excessive inflammatory response.
   
• For instance, the CDC reports that prompt treatment with antibiotics and fluid resuscitation can reduce sepsis-related mortality by up to 50%, underscoring the vital role of pharmacotherapy in managing severe cases.
   
• Furthermore, the growing use of combination therapies—such as pairing beta-lactam antibiotics with aminoglycosides and incorporating newer anti-inflammatory drugs—has led to better treatment outcomes and is contributing to the expansion of the market.

Based on disease type, the global sepsis therapeutics market is divided into mild sepsis, severe sepsis and septic shock. In 2024, the severe sepsis segment accounted for the largest share of 42.3% in global market.
 

• A significant amount of sepsis cases escalate to severe sepsis, which is the third most critical stage of sepsis marked by overwhelming inflammation and problematic organ failure. A case study report conducted by Geisinger Community Medical Center showed that 41 percent of reported cases of sepsis were registered in this category.
   
• The World Sepsis Federation reported that 49 million people affected by sepsis annually with severe sepsis being a leading factor for ICU admissions. This portion continues to increase because of increased hospitalization numbers, heightened awareness. along with the over implementation of pre-emptive measures of treatment.
   
• The growing threat of antimicrobial resistance (AMR) has further complicated infection management, often leading to more prolonged and severe sepsis cases. The surge in multidrug-resistant pathogens, particularly in hospital-acquired infections, has increased the incidence of severe sepsis that requires intensive care. This trend is driving demand for advanced treatment options and supportive care solutions, contributing to market expansion.
   
• Additionally, progress in diagnostic technologies—such as the use of biomarkers, rapid PCR testing, and AI-driven predictive tools—has significantly improved the early detection of severe sepsis. As a result, the ability to identify high-risk patients more quickly has enhanced clinical outcomes and fueled demand for advanced therapeutics, thereby accelerating market growth.
   

Based on end use, the global sepsis therapeutics market is categorized into hospitals, clinics and ambulatory surgical centers and other end users. The ambulatory surgical centers (ASCs) segment is growing with a significant CAGR and is expected to reach USD 1.8 billion by 2034.
 

• The rise of ambulatory surgical centers in sepsis treatment is stimulated by ability to provide quick and economical care compared to conventional hospital environments. The Ambulatory Surgery Centre Association (ASCA) states that ASCs are favoured for managing non-severe sepsis, with expenses 30-50% less than those in hospitals.
   
• Moreover, the utilisation of outpatient antibiotic therapy (OPAT) has helped patients with milder sepsis to obtain efficient treatment in ASCs, consequently, reduces the need for longer hospital stays. This shift aligns with global healthcare trends that promote decentralized care models to ease the burden on hospitals.
   
• Additionally, advancements in point-of-care testing, remote patient monitoring, and the integration of telehealth have allowed ASCs to handle sepsis cases more effectively, minimizing treatment delays and enhancing patient results.
   
• The growing preference for minimally invasive techniques is encouraging the broader adoption of ASCs as they offer quicker recovery time and reduced healthcare expenses.

In 2024, the U.S held a significant position in the North America sepsis therapeutics market, valued at USD 1.5 billion.
 

• The increasing cases of sepsis in the United States, driven by an aging population, antimicrobial resistance, and hospital-acquired infections, have increased the demand for advanced treatment options.
   
• According to a 2023 Centers for Disease Control and Prevention (CDC) report, approximately 1.7 million people in the United States are diagnosed with sepsis annually.
   
• Moreover, ongoing investment in sepsis research, innovation of new therapies and the incorporation of AI-based early diagnosis tools are fuelling the market growth.
   
• In addition, the key players in the market are involved in research and development activities to develop next-generation antimicrobials, biologics and sepsis-focused immunotherapies, that further contribute to market growth.
   

Germany dominates the European sepsis therapeutics market, showcasing strong growth potential.
 

• The increasing incidence of sepsis in Germany, combined with strong government initiatives towards infection control programs and well-developed healthcare infrastructure, is fuelling growth in the market.
   
• For example, the German Sepsis Society (GSS) and Sepsis Stiftung are actively working to raise awareness and enhancing treatment practices, increasing market uptake.
   
• In addition, Germany's robust pharmaceutical and biotechnology industry is majorly investing in research and development activities to introduce new sepsis therapies such as precision targeted antimicrobials and immune modulating therapy. The implementation of personalized sepsis treatment strategies, such as genetic profiling and bio markers-based therapy selection, is greatly improving patient outcomes.
   
• Moreover, the growing number of clinical trials for new sepsis medications, including BioVersys BV100 and Adrecizumab (Adrenomed), indicates the nation's strong position in the development of global sepsis therapeutics, further contributes to the market growth.
   

China sepsis therapeutics market is estimated to grow with a significant CAGR, making it to be the fastest growing country in the Asia Pacific market.
 

• China has the highest market share in the region, fueled by increasing hospital-acquired infections, a rapidly growing geriatric population and increasing ICU admissions.
   
• The increasing awareness of sepsis management, government efforts toward early detection of sepsis and increasing healthcare facilities have favoured China's National Health Commission (NHC) is launching national sepsis prevention programs, enhancing early detection and access to treatment.
   
• In addition, China's robust pharma sector is actively investing in the development of biologic medicines and new anti-sepsis therapies. The increasing collaborations with international biotech companies are facilitating the introduction of cutting-edge IV antibiotics, cytokines therapy and host-directed sepsis treatment, thereby contributing the market growth.
   
• China's increasing use of AI-based diagnostic tools and machine learning algorithms to predict sepsis and improve treatment is also stimulating market growth.
   

Brazil leads the Latin American sepsis therapeutics market, with remarkable growth during the analysis period.
 

• Gram negative bacteria are major cause of neonatal sepsis that are found in low and middle countries. According to 2023 Nature’s Communications journal, around 5.2% of 1,495 neonates suffer due to gram-negative bacteria that is around 2.9 per 1,000 patients per day.
   
• Brazil's high rate of infectious disease burden and growing antimicrobial resistance rates have compounded the incidence of sepsis. The government of Brazill has implemented strict hospital infection control measures and species management guidelines, enhancing early diagnosis and treatment access.
   
• In addition, partnership with international pharma companies have increased access to new sepsis therapies such as next-generation antibiotics and immunomodulators.
   
• The increased need for cost saving, hospital-based sepsis management solutions and increased public-private healthcare collaborations further stimulates market growth.
   

Saudi Arabia sepsis therapeutics market to experience substantial growth in the Middle East and Africa market in 2024.
 

• The growing numbers of specialized critical care units and rising government expenditures on healthcare infrastructure have spurred market development in Saudi Arabia.
   
• Moreover, the country is emphasizing early sepsis detection programs, AI-driven ICU monitoring systems, and hospital-based infection control programs to limit sepsis mortality rates.
   
• Additionally, the high prevalence of chronic conditions such as diabetes and cardiovascular disease in Saudi Arabia increases the risk of sepsis-related complications, thereby driving demand for effective antimicrobial therapies and critical care treatments.
   

Sepsis Therapeutics Market Share

Top 5 players such as F. Hoffmann La Roche, Abbott Laboratories, Pfizer, Cipla, and Astellas Pharma accounts for approximately 60%-70% of the market share. These players focus on various strategies such as business expansion, research and development activities, collaboration and novel product launches to consolidate their market presence. For instance, in April 2024, Prenosis collaborated with F. Hoffmann-La Roche to distribute their product named Sepsis Immmunoscore all over the U.S. country.
 

It is an Artificial intelligence and machine learning software as a medical which helped with rapid diagnosis of sepsis and helped predict any adverse effects. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for sepsis therapeutics treatment. The market is highly consolidated with only a few players operating in the market. Hence, leading players are constantly adopting key strategies for the growth of the market.
 

Sepsis Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are into clinical phase development. Prominent players operating in the sepsis therapeutics treatment market are as mentioned below:

• Abbott Laboratories
• Adrenomed
• Astellas Pharma
• Aurobindo Pharmaceuticals
• Aurora St. Luke’s Medical Center
• Azurity Pharmaceuticals
• Bosch Pharmaceuticals
• Christiana Hospital
• Cipla
• Drive DeVilbiss Healthcare
• F. Hoffmann-La Roche
• Medical Services Company
• Pfizer
• Torrent Pharmaceuticals
• West Virginia University Hospital
   

To stay competitive, key players are investing in research and development for the development of advanced or novel sepsis treatment solutions. These advancements are fostering increased competition, create awareness and stimulating growth across the market.
 

• Abbott integrates advanced nutritional therapy and diagnostic precision in sepsis care along with Oxepa providing targeted immunonutrition for reducuction of progression to severe sepsis, and the test offered for diagnosis of sepsis named B?R?A?H?M?S Procalcitonin (PCT) assay enables early, accurate diagnosis to guide timely antibiotic intervention.
   
• West Virginia University Hospital and others are raising awareness for sepsis and educating the public on the importance of early treatment during the Sepsis Survivor week held in February.
   
• AdrenoMed has distinguished itself in the sepsis market by receiving FDA Fast Track designation in April 2024 for its targeted precision medicine strategy. This approach focuses on addressing vascular dysfunction to reduce mortality rates from septic shock. By leveraging a biomarker-driven method, it supports personalized treatment, addressing a critical unmet need in intensive care.
   

Sepsis Therapeutics Industry News

• In August 2023, CDC launches a program named “Hospital Sepsis Program Core Elements” that supported all the U.S. hospitals for effective treatment and formation of teams for time-saving and early treatment of sepsis. The program enhanced sepsis treatment efficiency, leading to faster and more effective care in U.S. hospitals. 
   
• In March 2023, El Camino Health adopted FloPatch, an innovative new technology that monitors blood flow in real time developed by Flosonics Medical. FloPatch is the world’s first wireless, wearable Doppler ultra-sound system that helps clinicians better manage intravenous (IV) fluid therapy earlier in the sepsis care pathway. This helps clinicians monitor blood flow in real time, improving IV fluid management and enhancing early sepsis care.
   
• In December 2022, a medical diagnostic company named Cytovale, launched a product named IntelliSep sepsis test. This tool helps detecting sepsis providing results in 10 minutes, helping the decisive moment. The test categorizes patients into three bands according to the probability, where band 1 indicates low possibility and band 3 indicates higher one. This enables rapid sepsis detection, enhancing the company's market presence and supporting future development with secured funding.
   

The sepsis therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Drugs
  • Antibiotics
  • Anti-viral/ Anti-fungal
  • Other drugs 
• I.V fluids
• Oxygen therapy
• Surgery
• Other treatment types

Market, By Disease Type

• Mild sepsis
• Severe sepsis
• Septic shock

Market, By End Use

• Hospitals
• Clinics
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE